Form 4: Revance Therapeutics Director Angus C. Russell Reports Stock and Option Awards

Director Angus C. Russell reports acquisition of stock and option awards from Revance Therapeutics.

Summary

• On May 1, 2024, Angus C. Russell, a director of Revance Therapeutics, Inc., acquired 15,000 shares of common stock and options to purchase 23,458 shares of common stock.
• The common stock was acquired through a restricted stock award (RSA) granted under the company's Amended and Restated Non-Employee Director Compensation Policy.
• The shares underlying the RSA will vest on the earlier of May 1, 2025, or the day before the company's next annual stockholder meeting, contingent upon the director's continuous service.
• The stock options, with an exercise price of $3.795, also vest on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, subject to continuous service.
• Following these transactions, Russell directly owns 51,506 shares of common stock and options to purchase 23,458 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and aligns director interests with shareholders.

Positives

• The grant of stock and options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service by the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the awards.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies to align the interests of directors and management with shareholders.

Stakeholder Impact

• The stock and option awards align the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Revance Therapeutics, Director, Stock Award, Stock Option, Beneficial Ownership, RVNC, Form 4